Effect of Central Nervous System Dopaminergic Activation on Prolactin Secretion in Man: Evidence for a Common Central Defect in Hyperprolactinemic Patients with and without Radiological Signs of Pituitary Tumors*
Autor: | Pier Giorgio Crosignani, Maurizio Rocchetti, A.M. Mattei, C. Barbieri, Roberto Caldara, Aurelio Malinverni, Carlo Ferrari |
---|---|
Rok vydání: | 1980 |
Předmět: |
Adult
medicine.medical_specialty Pituitary gland Nomifensine Adolescent Endocrinology Diabetes and Metabolism Clinical Biochemistry Pharmacology Pituitary neoplasm Biochemistry Levodopa Endocrinology Internal medicine medicine Humans Pituitary Neoplasms Prolactinoma business.industry Biochemistry (medical) Pituitary tumors Dopaminergic Carbidopa medicine.disease Prolactin Kinetics medicine.anatomical_structure Female business medicine.drug |
Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 51:1068-1073 |
ISSN: | 1945-7197 0021-972X |
DOI: | 10.1210/jcem-51-5-1068 |
Popis: | Previously, it has been shown that the PRLsuppressive effect of L-dopa is unchanged by carbidopa pretreatment in healthy subjects but is markedly impaired in patients with PRL-secreting tumors, suggesting that the inhibitory action of L-dopa is mediated through the central nervous system (CNS) in normal humans and peripherally in patients with prolactinomas. Also, it has been claimed that the administration of nomifensine, a drug which stimulates CNS but not pituitary dopamine receptors, inhibits PRL secretion in hyperprolactinemic patients without, but not with, evidence of pituitary tumors. To further evaluate the possible diagnostic applications of these tests, Ldopa (500 mg) alone and 100 mg plus 35 mg carbidopa after carbidopa pretreatment (50 mg every 6 h) or nomifensine (200 mg) were administered orally to healthy subjects and patients with hyperprolactinemia of different etiology. The mean serum PRL concentration was similarly inhibited in normal subjects by L-dopa alone and by carbidopa plus L-do... |
Databáze: | OpenAIRE |
Externí odkaz: |